Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Update

Astrana Health, Inc. (NASDAQ:ASTH) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 1,490,000 shares, a drop of 8.6% from the December 31st total of 1,630,000 shares. Currently, 4.2% of the company’s stock are short sold. Based on an average daily trading volume, of 303,600 shares, the short-interest ratio is currently 4.9 days.

Astrana Health Stock Performance

Shares of ASTH stock traded up $0.14 during midday trading on Monday, hitting $37.01. The company had a trading volume of 71,167 shares, compared to its average volume of 377,685. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 1.42 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The company’s 50 day simple moving average is $36.27 and its 200 day simple moving average is $46.31. Astrana Health has a 52-week low of $29.08 and a 52-week high of $63.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period last year, the firm posted $0.47 EPS. Research analysts anticipate that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. KeyCorp began coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen assumed coverage on Astrana Health in a research report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price for the company. Truist Financial cut their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Finally, Robert W. Baird raised their target price on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $63.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Hussman Strategic Advisors Inc. purchased a new stake in Astrana Health in the 4th quarter valued at approximately $1,986,000. Handelsbanken Fonder AB grew its holdings in Astrana Health by 4.7% during the fourth quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company’s stock worth $281,000 after acquiring an additional 400 shares during the period. Truist Financial Corp purchased a new position in Astrana Health in the fourth quarter worth $315,000. State of New Jersey Common Pension Fund D lifted its holdings in Astrana Health by 25.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,287 shares of the company’s stock valued at $1,617,000 after acquiring an additional 10,389 shares during the period. Finally, E. Ohman J or Asset Management AB purchased a new stake in shares of Astrana Health during the 4th quarter worth $1,040,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.